These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35837161)

  • 61. State of the Art in the Treatment of Gastrointestinal Stromal Tumors.
    Garlipp B; Bruns CJ
    Gastrointest Tumors; 2014 May; 1(4):221-36. PubMed ID: 26672673
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gastrointestinal stromal tumor: a review of current and emerging therapies.
    Al-Share B; Alloghbi A; Al Hallak MN; Uddin H; Azmi A; Mohammad RM; Kim SH; Shields AF; Philip PA
    Cancer Metastasis Rev; 2021 Jun; 40(2):625-641. PubMed ID: 33876372
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Avances en tumores del estroma gastrointestinal: ¿hacia dónde vamos?
    Fernández-Hernández JA; Cantín-Blázquez S; García-Somacarrera E; Varo-Pérez E; González-López JA; Asencio-Pascual JM; Mendiola M; Serrano C; García-Granero E; Artigas-Raventós V
    Cir Cir; 2022; 90(2):267-277. PubMed ID: 35350056
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Regorafenib for treatment of advanced gastrointestinal stromal tumors.
    Overton LC; Heinrich MC
    Expert Opin Pharmacother; 2014 Mar; 15(4):549-58. PubMed ID: 24405315
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Optimal use of targeted agents for advanced gastrointestinal stromal tumours.
    Reichardt P
    Oncology; 2010; 78(2):130-40. PubMed ID: 20389135
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
    Rutkowski P; Magnan H; Chou AJ; Benson C
    BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Complete response to second-line chemotherapy with sunitinib of a gastrointestinal stromal tumor: A case report.
    Shirakawa T; Hirata T; Maemura K; Goto T; Shimao Y; Marutsuka K; Ueda Y; Kikuchi I
    Mol Clin Oncol; 2017 Jul; 7(1):93-97. PubMed ID: 28685083
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor.
    Cai Z; Chen X; Zhang B; Cao D
    Front Oncol; 2019; 9():470. PubMed ID: 31245289
    [No Abstract]   [Full Text] [Related]  

  • 71. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
    Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
    Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules.
    Vallilas C; Sarantis P; Kyriazoglou A; Koustas E; Theocharis S; Papavassiliou AG; Karamouzis MV
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33419029
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of and Current Trends in the Management of Gastrointestinal Stromal Tumors: A Systematic Review.
    Arzoun H; Srinivasan M; Adam M; Thomas SS; Kuta A; Sandoval S
    Cureus; 2022 Jul; 14(7):e26848. PubMed ID: 35847170
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery.
    Gouda MA; Janku F; Somaiah N; Hunt KK; Yedururi S; Subbiah V
    Oncoscience; 2023; 10():38-43. PubMed ID: 37736254
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.
    Chen YY; Yeh CN; Cheng CT; Chen TW; Rau KM; Jan YY; Chen MF
    World J Gastroenterol; 2011 Apr; 17(16):2113-9. PubMed ID: 21547131
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry.
    Call JW; Wang Y; Montoya D; Scherzer NJ; Heinrich MC
    Clin Sarcoma Res; 2019; 9():4. PubMed ID: 30984366
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
    Ishikawa T; Kanda T; Kosugi S; Yajima K; Hatakeyama K
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):916-21. PubMed ID: 21677482
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
    Lee DM; Sun A; Patil SS; Liu L; Rao AV; Trent PT; Ali AA; Liu C; Rausch JL; Presutti LD; Kaczorowski A; Schneider F; Amankulor NM; Shuda M; Duensing A
    Sci Rep; 2022 May; 12(1):8275. PubMed ID: 35585158
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study.
    Gelderblom H; Jones RL; George S; Valverde Morales C; Benson C; Jean-Yves Blay ; Renouf DJ; Doi T; Le Cesne A; Leahy M; Hertle S; Aimone P; Brandt U; Schӧffski P
    Br J Cancer; 2020 Apr; 122(8):1158-1165. PubMed ID: 32147671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.